Spironolactone in Post-Myocardial Infarction Cardiovascular Management
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 21st, 2025
|
The renin-angiotensin-aldosterone system plays a critical role in water retention. However, in heart failure patients, excessive fluid buildup can worsen the condition, so blocking this system with spironolactone has proven beneficial. Similarly, eplerenone—a drug closely related to spironolactone—has been effective in patients with myocardial infarction and reduced ejection fraction. Thus, a study funded by the Canadian Institutes of Health Research was conducted to evaluate the use of spironolactone in managing cardiovascular health after myocardial infarction.
The multinational study enrolled 7,062 participants with an average age of 60, all of whom had been hospitalized for myocardial infarction. Approximately 95% of these patients experienced ST-elevation myocardial infarction, and around half had blockages in multiple vessels. Prior to hospitalization, roughly 10% had a history of myocardial infarction, 45% had hypertension, and about 1% had heart failure. Patients were randomly assigned to receive either a placebo or spironolactone within two days of the onset of myocardial infarction. Spironolactone works by inhibiting the angiotensin-converting enzyme, thereby preventing the conversion of angiotensin I to angiotensin II. This inhibition reduces aldosterone production, leading to decreased water reabsorption by the nephron. After a median follow-up of three years, researchers found that spironolactone did not significantly lower the risk of death from recurrent myocardial infarction or stroke. Moreover, the treatment did not prevent exacerbations of heart failure or the onset of atrial fibrillation.
The multinational study enrolled 7,062 participants with an average age of 60, all of whom had been hospitalized for myocardial infarction. Approximately 95% of these patients experienced ST-elevation myocardial infarction, and around half had blockages in multiple vessels. Prior to hospitalization, roughly 10% had a history of myocardial infarction, 45% had hypertension, and about 1% had heart failure. Patients were randomly assigned to receive either a placebo or spironolactone within two days of the onset of myocardial infarction. Spironolactone works by inhibiting the angiotensin-converting enzyme, thereby preventing the conversion of angiotensin I to angiotensin II. This inhibition reduces aldosterone production, leading to decreased water reabsorption by the nephron. After a median follow-up of three years, researchers found that spironolactone did not significantly lower the risk of death from recurrent myocardial infarction or stroke. Moreover, the treatment did not prevent exacerbations of heart failure or the onset of atrial fibrillation.